Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2018064632) MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2018/064632 International Application No.: PCT/US2017/054611
Publication Date: 05.04.2018 International Filing Date: 29.09.2017
IPC:
C07D 401/14 (2006.01) ,C07D 471/14 (2006.01) ,C07D 498/14 (2006.01) ,A61K 31/4439 (2006.01) ,A61P 11/12 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
12
in which the condensed system contains three hetero rings
14
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
498
Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
12
in which the condensed system contains three hetero rings
14
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4427
containing further heterocyclic ring systems
4439
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
12
Mucolytics
Applicants:
VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 50 Northern Avenue Boston, MA 02210, US
Inventors:
ALCACIO, Timothy; US
BAEK, Minson; US
GROOTENHUIS, Peter; US
HADIDA RUAH, Sara Sabina; US
HUGHES, Robert M.; US
KESHAVARZ-SHOKRI, Ali; US
MCAULEY-AOKI, Rachel; US
MCCARTNEY, Jason; US
MILLER, Mark Thomas; US
VAN GOOR, Fredrick; US
ZHANG, Beili; US
ANDERSON, Corey; US
CLEVELAND, Thomas; US
FRIEMAN, Bryan A.; US
KHATUYA, Haripada; US
JOSHI, Pramod Virupax; US
KRENITSKY, Paul John; US
MELILLO, Vito; US
PIERRE, Fabrice Jean Denis; US
TERMIN, Andreas P.; US
UY, Johnny; US
ZHOU, Jinglan; US
ABELA, Alexander Russell; US
BUSCH, Brett Bradley; US
PARASELLI, Prasuna; US
SIESEL, David Andrew; US
Agent:
MACALPINE, Jill K.; US
RODRIGO, Christina, M.; US
Priority Data:
62/402,83830.09.2016US
62/410,35319.10.2016US
62/415,40931.10.2016US
62/419,93509.11.2016US
Title (EN) MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR
(FR) MODULATEUR DE RÉGULATEUR DE CONDUCTANCE TRANSMEMBRANAIRE DE FIBROSE KYSTIQUE, COMPOSITIONS PHARMACEUTIQUES, PROCÉDÉS DE TRAITEMENT ET PROCÉDÉ DE FABRICATION DU MODULATEUR
Abstract:
(EN) Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
(FR) L'invention concerne des composés de formule (I), des sels pharmaceutiquement acceptables de ceux-ci, des dérivés deutérés et des métabolites de l'un quelconque des précédents. L'invention concerne également des compositions pharmaceutiques les comprenant, des procédés de traitement de la fibrose kystique à l'aide de celles-ci, et des procédés de fabrication de celles-ci.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CA3037986AU2017336156CN109803962KR1020190067827BR112019006213